Compare Franco-Nevada Corporation (FNV) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs Invesco Ltd. — how do they compare? Franco-Nevada Corporation trades at $236.47 (market cap $45.36B), while Invesco Ltd. trades at $27.87 (market cap $12.33B). The key difference: Franco-Nevada Corporation is far larger — about 3.7× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (3.08%). Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Invesco Ltd. for 77 Days on average.
| FNV | IVZ | |
|---|---|---|
Market Cap | $45.36B | $12.33B |
Volume | 787,841 | 4,127,288 |
Sector | Basic Materials | Financials |
52-Week High | $280.82 | $33.31 |
52-Week Low | $183.97 | $22.44 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $44.34B | $22.50B |
Dividend Yield | 0.75% | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
Invesco (IVZ) trades at $28.92, down 1.16% with bearish technical signals despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $6.38B in 2025 but negative net margins of -0.93%. Analyst consensus remains cautiously optimistic with a $33.17 price target and no sell ratings, while technical indicators suggest near-term pressure with support at $28.
Investment outlook balances strong asset growth momentum (AUM up 4.7% to $2.56T in August 2026) against profitability challenges. Key opportunities include dividend yield and ETF expansion, while risks center on margin pressure and market volatility. The stock presents value potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
